Clinical Trials for April 2015 | Cancer Currents | Norris Cotton Cancer Center
Skip to main content
x
Norris Cotton Cancer Center
In This Section

Clinical Trials for April 2015

Konstantin Dragnev, Professor
Cancer Mechanism

Celgene
Safety and efficacy of nab-paclitaxel (Abraxane) in combination with carboplatin as first line treatment in elderly subjects with advanced Non-Small Cell Lung Cancer (NSCLC): A Phase IV, randomized, open-label multicenter study

Camilo Fadul, Professor
Immunology ad Cancer Immunotherapy

Alliance-NCI Cooperative Group
A Phase II/III randomized trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma with mgmt promoter hypermethylation

Lionel Lewis, Professor
Molecular Therapeutics

Novartis Pharmaceuticals
A Phase I, multi-center, randomized open label study to assess the systemic exposure and safety of 450 mg ceritinib taken with a low-fat meal and 600 mg ceritinib taken with a low-fat meal as compared with that of 750 mg ceritinib taken in the fasted state in adult patients with ALK rearranged (ALK-positive) metastatic non-small cell lung cancer (NSCLC)

Todd Miller, Assistant Professor
Molecular Therapeutics

PI/Department
Identifying mechanisms of resistance to mTOR inhibitors in cancer

J Marc Pipas, Professor
Molecular Therapeutics

Taiho
Protocol TO-TAS-102-401: An open label expanded access study of TAS-102 in patients with metastatic colorectal cancer refractory to or failing standard chemotherapy

Gary Schwartz, Associate Professor
Molecular Therapeutics

Millennium Pharmaceuticals, Inc

Phase I study of the combination of MLN9708 and fulvestrant in patients with advanced estrogen receptor-positive breast cancer

Bassem Zaki, Associate Professor
Cancer Imaging and Radiobiology

Medpace Immunomedics, Inc.
An international, multi-center, double-blind, randomized, Phase III trial of Y-clivatuzumab tetraxetan plus low-dose gemcitabine versus placebo plus low-dose gemcitabine in patients with metastatic (stage IV) pancreatic adenocarcinoma who received at least two prior treatments

0